Celcuity (CELC)
Celcuity on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as services-medical laboratories.
10.3M
Short interest
settlement 2026-10-15
5.8
Days to cover
-5.3 days vs prior
63.6%
Short share of volume
2026-10-28
43
Fails to deliver
settlement 2026-09-30
Wed 11 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-10-28.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in CELC is 10,252,223 shares, down 1,108,144 shares over the last month. Over the last 48 readings it ranged from 2,003,289 shares (15 April 2025) to 11,360,367 shares (15 September 2026). At the reported average volume of 1.8M shares a day that is 5.8 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/celc" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 10,252,223 | -6.6% | 1,778,375 | 5.76 |
| 2026-09-30 | 10,979,648 | -3.4% | 995,703 | 11.03 |
| 2026-09-15 | 11,360,367 | +6.3% | 910,327 | 12.48 |
| 2026-08-31 | 10,688,163 | +1.4% | 679,969 | 15.72 |
| 2026-08-14 | 10,535,416 | +2.6% | 796,592 | 13.23 |
| 2026-07-31 | 10,263,089 | -8.0% | 1,521,492 | 6.75 |
| 2026-07-15 | 11,152,374 | +1.7% | 1,967,354 | 5.67 |
| 2026-06-30 | 10,969,220 | +2.8% | 1,281,951 | 8.56 |
| 2026-06-15 | 10,666,555 | +11.1% | 2,452,131 | 4.35 |
| 2026-05-29 | 9,601,855 | +0.5% | 795,120 | 12.08 |
| 2026-05-15 | 9,558,186 | +7.1% | 1,601,340 | 5.97 |
| 2026-04-30 | 8,926,585 | +1.4% | 799,062 | 11.17 |
| 2026-04-15 | 8,802,926 | +0.0% | 688,257 | 12.79 |
| 2026-03-31 | 8,799,830 | -3.6% | 795,967 | 11.06 |
| 2026-03-13 | 9,128,797 | +0.2% | 702,889 | 12.99 |
| 2026-02-27 | 9,108,952 | -6.3% | 494,482 | 18.42 |
| 2026-02-13 | 9,719,315 | -1.2% | 737,527 | 13.18 |
| 2026-01-30 | 9,835,539 | +7.7% | 873,637 | 11.26 |
| 2026-01-15 | 9,133,962 | +3.2% | 648,232 | 14.09 |
| 2025-12-31 | 8,853,129 | +20.9% | 840,129 | 10.54 |
| 2025-12-15 | 7,321,648 | -1.0% | 888,810 | 8.24 |
| 2025-11-28 | 7,395,745 | +10.2% | 986,552 | 7.50 |
| 2025-11-14 | 6,709,486 | +13.4% | 806,551 | 8.32 |
| 2025-10-31 | 5,916,563 | -2.9% | 1,745,005 | 3.39 |
| 2025-10-15 | 6,091,043 | +25.1% | 1,191,808 | 5.11 |
| 2025-09-30 | 4,866,981 | -17.1% | 826,471 | 5.89 |
| 2025-09-15 | 5,867,404 | +4.4% | 836,205 | 7.02 |
| 2025-08-29 | 5,620,386 | +19.2% | 976,726 | 5.75 |
| 2025-08-15 | 4,714,098 | +52.6% | 1,201,822 | 3.92 |
| 2025-07-31 | 3,088,150 | +29.4% | 3,672,889 | 1.00 |
| 2025-07-15 | 2,386,654 | -1.1% | 206,243 | 11.57 |
| 2025-06-30 | 2,413,909 | -1.3% | 219,154 | 11.01 |
| 2025-06-13 | 2,444,767 | -1.4% | 157,066 | 15.57 |
| 2025-05-30 | 2,479,960 | +2.6% | 112,974 | 21.95 |
| 2025-05-15 | 2,416,077 | +13.9% | 194,900 | 12.40 |
| 2025-04-30 | 2,120,436 | +5.8% | 191,223 | 11.09 |
| 2025-04-15 | 2,003,289 | -35.5% | 491,110 | 4.08 |
| 2025-03-31 | 3,104,996 | -4.5% | 227,670 | 13.64 |
| 2025-03-14 | 3,250,391 | +9.7% | 322,886 | 10.07 |
| 2025-02-28 | 2,963,081 | -7.3% | 258,952 | 11.44 |
| 2025-02-14 | 3,196,639 | -3.9% | 170,264 | 18.77 |
| 2025-01-31 | 3,326,862 | +6.3% | 173,355 | 19.19 |
| 2025-01-15 | 3,128,118 | +13.2% | 355,675 | 8.79 |
| 2024-12-31 | 2,764,023 | -1.8% | 393,627 | 7.02 |
| 2024-12-13 | 2,814,410 | -1.9% | 177,743 | 15.83 |
| 2024-11-29 | 2,870,290 | -7.2% | 258,277 | 11.11 |
| 2024-11-15 | 3,091,176 | -11.4% | 350,502 | 8.82 |
| 2024-10-31 | 3,488,483 | -1.1% | 141,033 | 24.74 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 28 October 2026, the short share of CELC volume is 63.6%, down 7.0 points over the last five sessions. Over the last 30 readings it ranged from 19.0% (5 October 2026) to 85.7% (26 October 2026). The latest reading is 11.0 points above the 30-session average of 52.6%, on 343K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-28 | 218K | 343K | 63.6% | 0 |
| 2026-10-27 | 188K | 290K | 64.8% | 0 |
| 2026-10-26 | 896K | 1.0M | 85.7% | 30 |
| 2026-10-23 | 382K | 546K | 70.0% | 0 |
| 2026-10-22 | 453K | 651K | 69.6% | 148 |
| 2026-10-21 | 420K | 596K | 70.5% | 0 |
| 2026-10-20 | 256K | 519K | 49.3% | 0 |
| 2026-10-19 | 284K | 551K | 51.6% | 4,067 |
| 2026-10-16 | 544K | 1.4M | 38.9% | 15,360 |
| 2026-10-15 | 336K | 925K | 36.3% | 4 |
| 2026-10-14 | 354K | 967K | 36.6% | 1,564 |
| 2026-10-13 | 164K | 378K | 43.4% | 100 |
| 2026-10-12 | 204K | 468K | 43.6% | 1,365 |
| 2026-10-09 | 310K | 527K | 58.9% | 200 |
| 2026-10-08 | 257K | 860K | 29.8% | 5 |
| 2026-10-07 | 291K | 964K | 30.1% | 0 |
| 2026-10-06 | 300K | 640K | 46.9% | 0 |
| 2026-10-05 | 117K | 616K | 19.0% | 4 |
| 2026-10-02 | 215K | 709K | 30.3% | 24,100 |
| 2026-10-01 | 171K | 366K | 46.8% | 9 |
| 2026-09-30 | 798K | 1.3M | 63.4% | 100 |
| 2026-09-29 | 151K | 368K | 41.2% | 0 |
| 2026-09-28 | 120K | 264K | 45.6% | 0 |
| 2026-09-25 | 117K | 225K | 51.9% | 5 |
| 2026-09-24 | 142K | 434K | 32.8% | 0 |
| 2026-09-23 | 297K | 360K | 82.6% | 0 |
| 2026-09-22 | 109K | 165K | 65.8% | 27 |
| 2026-09-21 | 203K | 309K | 65.8% | 102 |
| 2026-09-18 | 156K | 247K | 63.0% | 50 |
| 2026-09-17 | 222K | 281K | 78.9% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 30 September 2026, the fails-to-deliver balance in CELC is 43 shares, down 743 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (21 July 2026) to 72,692 shares (28 July 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-30 | 43 | $77.38 | $3K |
| 2026-09-23 | 786 | $84.10 | $66K |
| 2026-09-21 | 335 | $80.61 | $27K |
| 2026-09-18 | 1,220 | $84.91 | $104K |
| 2026-09-16 | 7,975 | $82.70 | $660K |
| 2026-09-10 | 31,638 | $90.08 | $2.8M |
| 2026-09-08 | 31,865 | $95.70 | $3.0M |
| 2026-09-04 | 780 | $96.43 | $75K |
| 2026-09-03 | 816 | $96.20 | $78K |
| 2026-09-02 | 4,031 | $91.98 | $371K |
| 2026-08-25 | 4,328 | $90.79 | $393K |
| 2026-08-19 | 280 | $93.24 | $26K |
| 2026-08-11 | 6,045 | $90.79 | $549K |
| 2026-08-04 | 363 | $87.72 | $32K |
| 2026-07-30 | 48,400 | $83.26 | $4.0M |
| 2026-07-28 | 72,692 | $82.27 | $6.0M |
| 2026-07-22 | 713 | $91.69 | $65K |
| 2026-07-21 | 1 | $87.99 | $88 |
| 2026-07-16 | 32,189 | $91.51 | $2.9M |
| 2026-07-15 | 14,867 | $111.05 | $1.7M |
| 2026-07-10 | 7,484 | $113.51 | $850K |
| 2026-07-09 | 200 | $108.90 | $22K |
| 2026-07-08 | 200 | $115.72 | $23K |
| 2026-07-06 | 7,907 | $107.95 | $854K |
| 2026-07-02 | 8,261 | $104.49 | $863K |
| 2026-07-01 | 5,765 | $104.62 | $603K |
| 2026-06-30 | 22,193 | $102.52 | $2.3M |
| 2026-06-29 | 14,803 | $99.95 | $1.5M |
| 2026-06-26 | 10,216 | $95.93 | $980K |
| 2026-06-25 | 2,250 | $96.38 | $217K |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for CELC in the last 90 days. The most recent filings are listed below. Latest filing: Furcht Leo (Director) on 2026-10-07.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-07 | Furcht Leo | Director | Exercise or conversion | 250 | $7.60 | $2K | 13K |
| 2026-10-01 | GRYSKA DAVID W | Director | Grant | 893 | $0.00 | $0 | 893 |
| 2026-08-14 | Hahne Vicky | Chief Financial Officer | Grant | 16K | $0.00 | $0 | 38K |
| 2026-08-14 | Laing Lance G. | Chief Science Officer | Grant | 20K | $0.00 | $0 | 1.3M |
| 2026-08-14 | Sullivan Brian F. | Chief Executive Officer | Grant | 80K | $0.00 | $0 | 1.5M |
| 2026-07-14 | BAKER BROS. ADVISORS LP | Former 10% owner | Sell | 2.8M | $102.50 | $291.0M | 4.4M |
| 2026-07-14 | BAKER BROS. ADVISORS LP | Former 10% owner | Sell | 261K | $102.50 | $26.8M | 443K |
| 2026-06-05 | Murphy Polly A. | Director | Grant | 2K | $0.00 | $0 | 7K |
| 2026-06-05 | ROMP CHARLES R | Director | Grant | 2K | $0.00 | $0 | 2K |
| 2026-06-05 | Furcht Leo | Director | Grant | 2K | $0.00 | $0 | 13K |
| 2026-06-05 | Dalvey David | Director | Grant | 2K | $0.00 | $0 | 2K |
| 2026-06-05 | NIGON RICHARD | Director | Grant | 2K | $0.00 | $0 | 81K |
| 2026-06-05 | Buller Richard E | Director | Grant | 2K | $0.00 | $0 | 2K |
| 2026-06-02 | Laing Lance G. | Chief Science Officer | Exercise or conversion | 1K | $9.89 | $10K | 1.3M |
| 2026-05-19 | Buller Richard E | Director | Gift | 1K | $0.00 | $0 | 8K |
| 2026-05-19 | Buller Richard E | Director | Gift | 1K | $0.00 | $0 | 0 |
| 2026-05-04 | Dalvey David | Director | Sell | 25K | $140.68 | $3.5M | 65K |
| 2026-05-04 | Buller Richard E | Director | Sell | 365 | $143.24 | $52K | 7K |
| 2026-05-04 | Buller Richard E | Director | Sell | 3K | $142.04 | $401K | 7K |
| 2026-05-04 | Buller Richard E | Director | Sell | 2K | $141.03 | $325K | 10K |
| 2026-05-04 | Buller Richard E | Director | Sell | 2K | $139.58 | $233K | 12K |
| 2026-05-04 | Buller Richard E | Director | Sell | 550 | $139.00 | $76K | 14K |
| 2026-05-04 | Buller Richard E | Director | Sell | 1K | $137.00 | $177K | 14K |
| 2026-05-04 | Buller Richard E | Director | Exercise or conversion | 9K | $5.10 | $46K | 16K |
| 2026-04-09 | NIGON RICHARD | Director | Gift | 10K | $0.00 | $0 | 79K |
| 2026-03-31 | Buller Richard E | Director | Sell | 675 | $110.83 | $75K | 7K |
| 2026-03-31 | Buller Richard E | Director | Sell | 2K | $110.11 | $256K | 7K |
| 2026-03-31 | Buller Richard E | Director | Exercise or conversion | 3K | $5.10 | $15K | 10K |
| 2026-02-11 | ROMP CHARLES R | Director | Grant | 215 | $0.00 | $0 | 215 |
| 2026-01-27 | Dalvey David | Director | Sell | 20K | $120.03 | $2.4M | 90K |
| 2025-12-15 | NIGON RICHARD | Director | Gift | 20K | $0.00 | $0 | 89K |
| 2025-12-05 | Buller Richard E | Director | Sell | 2K | $106.04 | $160K | 7K |
| 2025-12-05 | Buller Richard E | Director | Sell | 1K | $105.34 | $157K | 8K |
| 2025-12-05 | Buller Richard E | Director | Exercise or conversion | 3K | $5.50 | $17K | 10K |
| 2025-12-04 | Furcht Leo | Director | Exercise or conversion | 250 | $7.60 | $2K | 11K |
| 2025-12-02 | Buller Richard E | Director | Gift | 500 | $0.00 | $0 | 7K |
| 2025-12-01 | Buller Richard E | Director | Sell | 1K | $98.13 | $108K | 7K |
| 2025-12-01 | Buller Richard E | Director | Exercise or conversion | 1K | $14.83 | $16K | 8K |
| 2025-11-21 | Dalvey David | Director | Sell | 15K | $100.00 | $1.5M | 110K |
| 2025-11-20 | Buller Richard E | Director | Sell | 4K | $96.73 | $377K | 7K |
| 2025-11-20 | Buller Richard E | Director | Exercise or conversion | 4K | $14.83 | $58K | 11K |
| 2025-11-19 | Buller Richard E | Director | Gift | 500 | $0.00 | $0 | 7K |
| 2025-09-11 | NIGON RICHARD | Director | Exercise (in or at the money) | 3K | $7.56 | $25K | 109K |
| 2025-09-11 | NIGON RICHARD | Director | Exercise (in or at the money) | 5K | $7.56 | $35K | 106K |
| 2025-09-08 | Baker Bros. Advisors (GP) LLC | TenPercentOwner | Buy | 14K | $56.22 | $786K | 704K |
| 2025-09-08 | Baker Bros. Advisors (GP) LLC | TenPercentOwner | Buy | 152K | $56.22 | $8.5M | 7.2M |
| 2025-09-08 | Baker Bros. Advisors (GP) LLC | TenPercentOwner | Buy | 388 | $58.02 | $23K | 704K |
| 2025-09-08 | Baker Bros. Advisors (GP) LLC | TenPercentOwner | Buy | 4K | $58.02 | $244K | 7.2M |
| 2025-09-08 | BAKER BROS. ADVISORS LP | 10% owner | Buy | 4K | $58.02 | $244K | 7.2M |
| 2025-09-08 | BAKER BROS. ADVISORS LP | 10% owner | Buy | 388 | $58.02 | $23K | 704K |
| 2025-09-08 | BAKER BROS. ADVISORS LP | 10% owner | Buy | 152K | $56.22 | $8.5M | 7.2M |
| 2025-09-08 | BAKER BROS. ADVISORS LP | 10% owner | Buy | 14K | $56.22 | $786K | 704K |
| 2025-09-02 | Sullivan Brian F. | Chief Executive Officer | Exercise (in or at the money) | 104K | $8.05 | $840K | 1.4M |
| 2025-07-28 | Dalvey David | Director | Sell | 4K | $46.05 | $191K | 125K |
| 2025-07-28 | Dalvey David | Director | Sell | 16K | $45.29 | $744K | 129K |
| 2025-07-28 | Dalvey David | Director | Sell | 22K | $44.36 | $993K | 146K |
| 2025-07-28 | Dalvey David | Director | Sell | 57K | $43.30 | $2.5M | 168K |
| 2025-07-28 | Dalvey David | Director | Sell | 2K | $46.05 | $93K | 0 |
| 2025-07-28 | Dalvey David | Director | Sell | 4K | $45.24 | $188K | 2K |
| 2025-07-28 | Dalvey David | Director | Sell | 3K | $44.36 | $139K | 6K |
| 2025-05-27 | Buller Richard E | Director | Gift | 1K | $0.00 | $0 | 1K |
| 2025-05-27 | Buller Richard E | Director | Gift | 1K | $0.00 | $0 | 8K |
| 2025-05-19 | Buller Richard E | Director | Grant | 1K | $0.00 | $0 | 2K |
| 2025-04-14 | Sullivan Brian F. | Chief Executive Officer | Gift | 8K | $0.00 | $0 | 1.3M |
| 2025-04-14 | Sullivan Brian F. | Chief Executive Officer | Gift | 8K | $0.00 | $0 | 0 |
| 2025-03-04 | Sullivan Brian F. | Chief Executive Officer | Gift | 37K | $0.00 | $0 | 8K |
| 2025-03-04 | Sullivan Brian F. | Chief Executive Officer | Gift | 37K | $0.00 | $0 | 803K |
| 2025-03-03 | Sullivan Brian F. | Chief Executive Officer | Gift | 45K | $0.00 | $0 | 1.3M |
| 2025-03-03 | Sullivan Brian F. | Chief Executive Officer | Gift | 40K | $0.00 | $0 | 1.3M |
| 2025-03-03 | Sullivan Brian F. | Chief Executive Officer | Gift | 45K | $0.00 | $0 | 45K |
| 2025-03-03 | Sullivan Brian F. | Chief Executive Officer | Gift | 40K | $0.00 | $0 | 948K |
| 2024-12-02 | Furcht Leo | Director | Exercise or conversion | 250 | $3.60 | $900 | 11K |
| 2024-10-23 | Buller Richard E | Director | Sell | 350 | $16.25 | $6K | 7K |
| 2024-08-23 | Buller Richard E | Director | Sell | 350 | $16.95 | $6K | 7K |
| 2024-08-20 | Sullivan Brian F. | Chief Executive Officer | Gift | 189K | $0.00 | $0 | 1.3M |
| 2024-08-20 | Sullivan Brian F. | Chief Executive Officer | Gift | 189K | $0.00 | $0 | 0 |
| 2024-06-21 | Buller Richard E | Director | Sell | 350 | $15.68 | $5K | 7K |
| 2024-06-10 | NIGON RICHARD | Director | Exercise (in or at the money) | 5K | $9.50 | $48K | 101K |
| 2024-06-04 | Buller Richard E | Director | Grant | 1K | $0.00 | $0 | 7K |
| 2024-05-22 | Buller Richard E | Director | Gift | 2K | $0.00 | $0 | 2K |
| 2024-05-22 | Buller Richard E | Director | Gift | 2K | $0.00 | $0 | 6K |
| 2024-04-26 | Sullivan Brian F. | Chief Executive Officer | Gift | 45K | $0.00 | $0 | 908K |
| 2024-04-26 | Sullivan Brian F. | Chief Executive Officer | Gift | 45K | $0.00 | $0 | 1.2M |
| 2024-04-24 | Buller Richard E | Director | Sell | 350 | $17.06 | $6K | 8K |
| 2024-03-18 | Sullivan Brian F. | Chief Executive Officer | Gift | 766K | $0.00 | $0 | 766K |
| 2024-03-18 | Sullivan Brian F. | Chief Executive Officer | Gift | 766K | $0.00 | $0 | 189K |
| 2024-02-21 | Buller Richard E | Director | Sell | 350 | $14.15 | $5K | 8K |
| 2024-01-30 | Sullivan Brian F. | Chief Executive Officer | Gift | 85K | $0.00 | $0 | 1.2M |
| 2024-01-30 | Sullivan Brian F. | Chief Executive Officer | Gift | 85K | $0.00 | $0 | 955K |
| 2023-12-27 | Sullivan Brian F. | Chief Executive Officer | Gift | 870K | $0.00 | $0 | 870K |
| 2023-12-27 | Sullivan Brian F. | Chief Executive Officer | Gift | 863K | $0.00 | $0 | 863K |
| 2023-12-27 | Sullivan Brian F. | Chief Executive Officer | Gift | 1.7M | $0.00 | $0 | 1.3M |
| 2023-12-20 | Buller Richard E | Director | Sell | 350 | $14.37 | $5K | 8K |
| 2023-12-15 | Dalvey David | Director | Sell | 3K | $14.57 | $43K | 225K |
| 2023-12-14 | Dalvey David | Director | Sell | 5K | $14.75 | $74K | 228K |
| 2023-12-13 | Dalvey David | Director | Sell | 5K | $14.50 | $73K | 233K |
| 2023-12-12 | Dalvey David | Director | Sell | 2K | $14.61 | $30K | 238K |
| 2023-12-08 | Dalvey David | Director | Sell | 5K | $15.00 | $75K | 240K |
| 2023-12-07 | Dalvey David | Director | Sell | 5K | $14.85 | $74K | 245K |
| 2023-11-28 | Furcht Leo | Director | Exercise or conversion | 250 | $1.60 | $400 | 11K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON10 Form 144 notices on file for CELC worth $327.5M at the prices reported; 0 in the last 90 days worth $0. Latest: Baker Brothers Life Sciences, L.P. filed on 2026-07-14 to sell 2,838,632 shares ($291.0M) from 2026-07-14.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-07-14 | Baker Brothers Life Sciences, L.P.Former Affiliate | 2.8M | $291.0M | 5.821% | 2026-07-14 | Goldman Sachs & Co. LLC |
| 2026-07-14 | 667, L.P.Former Affiliate | 261K | $26.8M | 0.536% | 2026-07-14 | Goldman Sachs & Co. LLC |
| 2026-05-04 | Dalvey DavidDirector | 25K | $3.5M | 0.054% | 2026-05-04 | RBC CAPITAL MARKETS LLC |
| 2026-05-04 | Buller Richard EDirector | 6K | $843K | 0.012% | 2026-05-04 | Stifel Nicolaus & Company Inc |
| 2026-03-31 | Buller Richard EDirector | 6K | $662K | 0.012% | 2026-03-31 | Stifel Nicolaus & Company Inc |
| 2026-01-27 | Dalvey DavidDirector | 20K | $2.4M | 0.043% | 2026-01-27 | RBC CAPITAL MARKETS LLC |
| 2025-12-05 | Buller Richard EDirector | 3K | $317K | 0.006% | 2025-12-05 | Stifel Nicolaus & Company Inc |
| 2025-12-01 | Buller Richard EDirector | 1K | $108K | 0.002% | 2025-12-01 | Stifel Nicolaus & Company Inc |
| 2025-11-21 | Dalvey DavidDirector | 15K | $1.5M | 0.032% | 2025-11-21 | RBC CAPITAL MARKETS LLC |
| 2025-11-20 | Buller Richard EDirector | 4K | $377K | 0.008% | 2025-11-20 | Stifel Nicolaus & Company Inc |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON13 holders report 5% or more of CELC in their latest filing, all on Schedule 13G (passive). The largest reported stake is Baker Bros. Advisors LP at 10.0% of the class (4,877,963 shares), filed 2026-07-16 for an event on 2026-07-14.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-11 | 13G | BANK OF AMERICA CORP /DE/parent holding company | 3.2M | 6.5% | 2026-06-30 |
| 2026-07-16 | 13G | Baker Bros. Advisors LPinvestment adviser, partnership | 4.9M | 10.0% | 2026-07-14 |
| 2026-07-16 | 13G | Baker Bros. Advisors (GP) LLCparent holding company, other entity | 4.9M | 10.0% | 2026-07-14 |
| 2026-07-16 | 13G | Julian C. Bakerparent holding company, individual | 4.9M | 10.0% | 2026-07-14 |
| 2026-07-16 | 13G | Felix J. Bakerparent holding company, individual | 4.9M | 10.0% | 2026-07-14 |
| 2026-05-15 | 13G | RTW Investments, LPinvestment adviser, partnership | 3.0M | 6.3% | 2026-03-31 |
| 2026-05-15 | 13G | Roderick Wongparent holding company, individual | 3.0M | 6.3% | 2026-03-31 |
| 2026-03-09 | 13D/Ano. 4 | NEA 18 Venture Growth Equity, L.P.partnership | 2.3M | 4.9% | 2026-03-05 |
| 2026-03-09 | 13D/Ano. 4 | Growth Equity Opportunities 18 VGE, LLCother entity | 2.3M | 4.9% | 2026-03-05 |
| 2026-03-09 | 13D/Ano. 4 | NEA Partners 18 VGE, L.P.partnership | 2.3M | 4.9% | 2026-03-05 |
| 2026-03-09 | 13D/Ano. 4 | NEA 18 VGE GP, LLCother entity | 2.3M | 4.9% | 2026-03-05 |
| 2026-03-09 | 13D/Ano. 4 | Ali Behbahaniindividual | 2.3M | 4.9% | 2026-03-05 |
| 2026-03-09 | 13D/Ano. 4 | Carmen Changindividual | 2.3M | 4.9% | 2026-03-05 |
| 2026-03-09 | 13D/Ano. 4 | Anthony A. Florence, Jr.individual | 2.3M | 4.9% | 2026-03-05 |
| 2026-03-09 | 13D/Ano. 4 | Mohamad H. Makhzoumiindividual | 2.3M | 4.9% | 2026-03-05 |
| 2026-03-09 | 13D/Ano. 4 | Edward T. Mathersindividual | 2.3M | 4.9% | 2026-03-05 |
| 2026-03-09 | 13D/Ano. 4 | Scott D. Sandellindividual | 2.3M | 4.9% | 2026-03-05 |
| 2026-03-09 | 13D/Ano. 4 | Paul Walkerindividual | 2.3M | 4.9% | 2026-03-05 |
| 2026-03-09 | 13D/Ano. 4 | Rick Yangindividual | 2.3M | 4.9% | 2026-03-05 |
| 2026-02-17 | 13G/Ano. 1 | Perceptive Advisors LLCinvestment adviser | 3.2M | 6.8% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | Joseph Edelmanindividual | 3.2M | 6.8% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | Perceptive Life Sciences Master Fund, Ltd.corporation | 3.2M | 6.8% | 2025-12-31 |
| 2026-02-17 | 13G | Avoro Capital Advisors LLCinvestment adviser, other entity | 3.1M | 6.7% | 2025-12-31 |
| 2026-02-17 | 13G | Behzad Aghazadehparent holding company, individual | 3.1M | 6.7% | 2025-12-31 |
| 2026-02-12 | 13G/Ano. 5 | Soleus Capital Management, L.P.partnership | 1.8M | 3.9% | 2025-12-31 |
| 2026-02-12 | 13G/Ano. 5 | Guy Levyindividual | 1.8M | 3.9% | 2025-12-31 |
| 2026-02-12 | 13G/Ano. 5 | Soleus GP, LLCother entity | 1.8M | 3.9% | 2025-12-31 |
| 2026-02-12 | 13G/Ano. 5 | Soleus Capital Master Fund, L.P.non-US institution | 1.7M | 3.6% | 2025-12-31 |
| 2026-02-12 | 13G/Ano. 5 | Soleus Capital, LLCother entity | 1.7M | 3.6% | 2025-12-31 |
| 2026-02-12 | 13G/Ano. 5 | Soleus Capital Group, LLCother entity | 1.7M | 3.6% | 2025-12-31 |
| 2026-02-12 | 13G/Ano. 5 | Soleus Private Equity Fund II, L.P.partnership | 142K | 0.3% | 2025-12-31 |
| 2026-02-12 | 13G/Ano. 5 | Soleus Private Equity GP II, LLCother entity | 142K | 0.3% | 2025-12-31 |
| 2026-02-12 | 13G/Ano. 5 | Soleus PE GP II, LLCother entity | 142K | 0.3% | 2025-12-31 |
| 2025-11-14 | 13G/Ano. 1 | BVF PARTNERS L P/ILinvestment adviser, partnership | 658K | 1.6% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | LAMPERT MARK Nindividual | 658K | 1.6% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | BVF INC/ILcorporation | 658K | 1.6% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | BVF GP HOLDINGS LLCother entity | 609K | 1.4% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | BIOTECHNOLOGY VALUE FUND L Ppartnership | 340K | 0.8% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | BVF I GP LLCother entity | 340K | 0.8% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | BVF II GP LLCother entity | 269K | 0.6% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | BIOTECHNOLOGY VALUE FUND II LPpartnership | 269K | 0.6% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | BVF Partners OS Ltd.corporation | 36K | 0.1% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | Biotechnology Value Trading Fund OS LPpartnership | 36K | 0.1% | 2025-09-30 |
| 2025-11-13 | 13G/Ano. 6 | Brian F. Sullivanindividual | 4.0M | 9.1% | 2025-09-30 |
| 2025-11-13 | 13G/Ano. 6 | Lance G. Laingindividual | 1.6M | 3.6% | 2025-09-30 |
13F holders
Tracked managers holding CELC at their latest 13F. JSON4 of the 30 tracked managers held CELC at their latest 13F, $72.8M in total at quarter-end prices. Point72 Asset Management is the largest at $68.1M (0.1% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 1 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Point72 Asset Management | 2026-06-30 | 651K | $68.1M | 0.08% | +371K |
| D. E. Shaw & Co. | 2026-06-30 | 30K | $3.2M | 0.00% | +10K |
| AQR Capital Management | 2026-06-30 | 13K | $1.3M | 0.00% | -5K |
| Fisher Asset Management | 2026-06-30 | 2K | $209K | 0.00% | new |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn FY 2025 it generated -$153.3M of operating cash flow. As of 2026-06-30, cash was $182.0M against $0 of debt.
- Cash
- $182.0M
- Debt
- $0
- Equity
- -$12.8M
- Total assets
- $828.2M
- Shares outstanding
- 48,931,908
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | n/a | -$78.9M | n/a | -1.44 |
| Q1 FY 2026 | 2026-03-31 | n/a | -$52.8M | n/a | -0.97 |
| Q4 FY 2025derived | 2025-12-31 | n/a | -$51.0M | n/a | n/a |
| Q3 FY 2025 | 2025-09-30 | n/a | -$43.8M | n/a | -0.92 |
| Q2 FY 2025 | 2025-06-30 | n/a | -$45.3M | n/a | -1.04 |
| Q1 FY 2025 | 2025-03-31 | n/a | -$37.0M | n/a | -0.86 |
| Q4 FY 2024derived | 2024-12-31 | n/a | -$36.7M | n/a | n/a |
| Q3 FY 2024 | 2024-09-30 | n/a | -$29.8M | n/a | -0.70 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | n/a | -$177.0M | -$153.3M | $249K | n/a | n/a |
| FY 2024 | 2024-12-31 | n/a | -$111.8M | -$83.5M | $250K | n/a | n/a |
| FY 2023 | 2023-12-31 | n/a | -$63.8M | -$53.8M | $98K | n/a | n/a |
| FY 2022 | 2022-12-31 | n/a | -$40.4M | -$36.0M | $159K | n/a | n/a |
| FY 2021 | 2021-12-31 | n/a | -$29.6M | -$20.3M | $82K | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-08-05 from the cover page.
What this page is
Celcuity in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Celcuity (CELC), SEC CIK 1603454, listed on Nasdaq, classified by the SEC as services-medical laboratories. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-28.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-30.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-07-14.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-11.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-05-14.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-07.JSON and CSV
- Company record
- EDGAR filing index for CIK 1603454Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as services-medical laboratories
Other company pages
Datasets
Frequently Asked Questions
How much of CELC is sold short?
10,252,223 shares were held short at the 2026-10-15 settlement, 5.8 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is CELC's daily short volume?
On 2026-10-28, 217,809 of the 342,582 CELC shares reported to FINRA were sold short, 63.6% of the day's reported volume. Short volume is a flow for one day, not a position.
Does CELC have fails to deliver?
The SEC's latest file shows 43 CELC shares failed to deliver at settlement 2026-09-30. Fails are reported per settlement date and published twice a month with a lag.
Are CELC insiders buying or selling?
No open-market insider trades were reported for CELC in the last 90 days. The most recent filings are listed below. Latest filing: Furcht Leo (Director) on 2026-10-07.
Have CELC insiders filed to sell?
10 Form 144 notices on file for CELC worth $327.5M at the prices reported; 0 in the last 90 days worth $0. Latest: Baker Brothers Life Sciences, L.P. filed on 2026-07-14 to sell 2,838,632 shares ($291.0M) from 2026-07-14.
Who owns 5% or more of CELC?
13 holders report 5% or more of CELC in their latest filing, all on Schedule 13G (passive). The largest reported stake is Baker Bros. Advisors LP at 10.0% of the class (4,877,963 shares), filed 2026-07-16 for an event on 2026-07-14.
What did CELC report last quarter?
In FY 2025 it generated -$153.3M of operating cash flow. As of 2026-06-30, cash was $182.0M against $0 of debt.
Which tracked 13F managers own CELC?
4 of the 30 tracked 13F managers held CELC shares at their latest filing, $72.8M in all. The largest: Steve Cohen's Point72 Asset Management (651K shares, $68.1M), D. E. Shaw & Co. (30K shares, $3.2M), Cliff Asness's AQR Capital Management (13K shares, $1.3M), Ken Fisher's Fisher Asset Management (2K shares, $209K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.